RBCC JV Target Amarantus Presents Parkinson’s Therapeutic at CNS Summit

NOKOMIS, Fla.--(BUSINESS WIRE)--

As Rainbow Coral Corp. (RBCC) nears a new joint venture agreement to commercialize advances made by Amarantus BioSciences (AMBS), the companys latest target continues to seek out additional investment capital from high-profile investors.

Amarantus Chief Science Officer John W. Commissiong recently presented his organizations brilliant MANF therapeutic protein for Parkinsons disease at the Scientific Session of CNS Summit 2012 in Boca Raton. The CNS Summit brings together researchers, developers and investors to collaborate in bringing new treatments to patients suffering from brain disorders.

The high-profile event put Amarantus proprietary, anti-apoptosis therapeutic protein in the spotlight in front of researchers and investors from around the world.

We continue to be very impressed with Amarantus outreach efforts toward potential investors and clients alike, said RBCC CEO Patrick Brown. We look forward to wrapping up our joint venture agreement shortly, and then our first priority will be moving their groundbreaking therapeutics forward toward full commercialization.

Both companies forswear realizing revenues from the impending commercialization of Amarantus NuroPro, a sophisticated test developed to more accurately and easily diagnose Parkinsons disease. By cutting the typical timeline from years to only one year, RBCC and its shareholders believe they will see larger profits more quickly from the deal. Next in line for commercialization will be MANF.

For more information on Rainbow BioSciences neurological treatment initiatives, please visitwww.rainbowbiosciences.com/investors.html.

RainbowBioSciences is dedicated to developing new medical and research technology innovations to compete alongside companies such as Amgen Inc. (NASDAQ:AMGN),Cell Therapeutics, Inc. (NASDAQ:CTIC), Abbott Laboratories (NYSE:ABT) andAffymax, Inc.(NASDAQ:AFFY).

About Rainbow BioSciences

Rainbow BioSciences, LLC, is a wholly owned subsidiary of Rainbow Coral Corp. (OTCBB:RBCC). The company continually seeks out new partnerships with biotechnology developers to deliver profitable new medical technologies and innovations. For more information on our growth-oriented business initiatives, please visit our website at [www.RainbowBioSciences.com]. For investment information and performance data on the company, please visit http://www.RainbowBioSciences.com/investors.html.

Continued here:
RBCC JV Target Amarantus Presents Parkinson’s Therapeutic at CNS Summit